Comparison of the efficacy of early versus late viral proteins in vaccination against SIV

被引:44
作者
Stittelaar, KJ
Gruters, RA
Schutten, M
van Baalen, CA
van Amerongen, G
Cranage, M
Liljeström, P
Sutter, G
Osterhaus, ADME
机构
[1] GSF, Inst Mol Virol, D-85764 Neuherberg, Germany
[2] Karolinska Inst, Microbiol & Tumorbiol Ctr, Stockholm, Sweden
[3] CAMR, Salisbury, Wilts, England
[4] Ecole Normale Super Lyon, BioMerieux, CNRS, UMR 2142, F-69364 Lyon, France
[5] Erasmus Med Ctr Rotterdam, Dept Virol, NL-3015 GE Rotterdam, Netherlands
关键词
Tat; Rev; CTL;
D O I
10.1016/S0264-410X(02)00219-0
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The immune response against early regulatory proteins of simian- and human immunodeficiency virus (SIV, HIV) has been associated with a milder course of infection. Here, we directly compared vaccination with Tat/Rev versus Pol/Gag. Challenge infection with SIVmac32H (pJ5) suggested that vaccination with Tat/Rev induced cellular immune responses that enabled cynomolgus macaques to more efficiently control SIV replication than the vaccine-induced immune responses against Pol/Gag. Vaccination with Tat/Rev resulted in reduced plasma SIV loads compared with control (P = 0.058) or Pol/Gag-vaccinated (P =. 0.089) animals, with undetectable plasma viral loads in two of the four Tat/Rev-vaccinated animals. Therefore, the results warrant further investigation of the early regulatory proteins and their potential for vaccination against HIV. (C) 2002 Published by Elsevier Science Ltd.
引用
收藏
页码:2921 / 2927
页数:7
相关论文
共 18 条
[1]   The HIV-1 regulatory proteins Tat and Rev are frequently targeted by cytotoxic T lymphocytes derived from HIV-1-infected individuals [J].
Addo, MM ;
Altfeld, M ;
Rosenberg, ES ;
Eldridge, RL ;
Philips, MN ;
Habeeb, K ;
Khatri, A ;
Brander, C ;
Robbins, GK ;
Mazzara, GP ;
Goulder, PJR ;
Walker, BD .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (04) :1781-1786
[2]   Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia [J].
Allen, TM ;
O'Connor, DH ;
Jing, PC ;
Dzuris, JL ;
Mothé, BR ;
Vogel, TU ;
Dunphy, E ;
Liebl, ME ;
Emerson, C ;
Wilson, N ;
Kunstman, KJ ;
Wang, XC ;
Allison, DB ;
Hughes, AL ;
Desrosiers, RC ;
Altman, JD ;
Wolinsky, SM ;
Sette, A ;
Watkins, DI .
NATURE, 2000, 407 (6802) :386-390
[3]   DNA vaccination for HIV-1 and SIV [J].
Barouch, DH ;
Letvin, NL .
INTERVIROLOGY, 2000, 43 (4-6) :282-287
[4]   Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine [J].
Cafaro, A ;
Caputo, A ;
Fracasso, C ;
Maggiorella, MT ;
Goletti, D ;
Baroncelli, S ;
Pace, M ;
Sernicola, L ;
Koanga-Mogtomo, ML ;
Betti, M ;
Borsetti, A ;
Belli, R ;
Åkerblom, L ;
Corrias, F ;
Buttò, S ;
Heeney, J ;
Verani, P ;
Titti, F ;
Ensoli, B .
NATURE MEDICINE, 1999, 5 (06) :643-650
[5]   Decline of simian immunodeficiency virus (SIV)-specific cytotoxic T lymphocytes in the peripheral blood of long-term nonprogressing macaques infected with SIVmac32H-J5 [J].
Geretti, AM ;
Hulskotte, EGJ ;
Dings, MEM ;
van Baalen, CA ;
van Amerongen, G ;
Norley, SG ;
Boers, P ;
Gruters, R ;
Osterhaus, ADME .
JOURNAL OF INFECTIOUS DISEASES, 1999, 180 (04) :1133-1141
[6]  
Hirsch V M, 2000, Adv Pharmacol, V49, P437
[7]   VACCINE-INDUCED VIRUS-NEUTRALIZING ANTIBODIES AND CYTOTOXIC T-CELLS DO NOT PROTECT MACAQUES FROM EXPERIMENTAL-INFECTION WITH SIMIAN IMMUNODEFICIENCY VIRUS SIVMAC32H (J5) [J].
HULSKOTTE, EGJ ;
GERETTI, AM ;
SIEBELINK, KHJ ;
VANAMERONGEN, G ;
CRANAGE, MP ;
RUD, EW ;
NORLEY, SG ;
DEVRIES, P ;
OSTERHAUS, ADME .
JOURNAL OF VIROLOGY, 1995, 69 (10) :6289-6296
[8]   Vaccines for the prevention of HIV-1 disease [J].
Mascola, JR ;
Nabel, GJ .
CURRENT OPINION IN IMMUNOLOGY, 2001, 13 (04) :489-495
[9]   Cellular immune responses to HIV [J].
McMichael, AJ ;
Rowland-Jones, SL .
NATURE, 2001, 410 (6831) :980-987
[10]   Biological considerations in the development of a human immunodeficiency virus vaccine [J].
Nathanson, N ;
Mathieson, BJ .
JOURNAL OF INFECTIOUS DISEASES, 2000, 182 (02) :579-589